Hepatitis B virus: From diagnosis to treatment;Virus de l'hépatite B: du diagnostic au traitement

Pathologie Biologie

Volumn 58, Issue 4, 2010, Pages 245-253

  Deny P ^a,b   Zoulim, F ^a,c,d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c UNIVERSITÉ LYON 1   (France)

^d UNIVERSITÉ DE LYON   (France)

Author keywords

Diagnosis; Genotype; HBV; Hepadnaviridae; Resistance; Treatment; Virus of hepatitis B

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ENTECAVIR; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PLACEBO; PROTHROMBIN; RNA DIRECTED DNA POLYMERASE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ANTIVIRAL RESISTANCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; COMORBIDITY; DISEASE COURSE; DNA DETERMINATION; DRUG TREATMENT FAILURE; ECHOGRAPHY; FATIGUE; FOLLOW UP; HEALTH CARE POLICY; HEALTH PROGRAM; HEPATITIS B; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; JAUNDICE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MULTIDRUG RESISTANCE; NAUSEA; PATIENT CARE; POLYMERASE CHAIN REACTION; PROTHROMBIN TIME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROCONVERSION; SURVIVAL RATE; SYMPTOM; URINE COLOR; VIRUS MUTANT; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INFANT, NEWBORN; LIVER DISEASES; LIVER NEOPLASMS; MASS VACCINATION; VIRUS REPLICATION;

EID: 77955416232     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2010.05.002     Document Type: Article

References (65)

1. Kurbanov F., Tanaka Y., Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res 2010, 40:14-30.
2. Villeneuve J.P. The natural history of chronic hepatitis B virus infection. J Clin Virol 2005, 34(Suppl 1):S139-S142.
3. Ganem D., Prince A.M. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004, 350:1118-1129.
4. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., Lok A.S. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007, 45:1056-1075.
5. Liaw Y.F., Leung N., Kao J.H., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008, 2:263-283.
6. Schutte K., Bornschein J., Malfertheiner P. Hepatocellular carcinoma - epidemiological trends and risk factors. Dig Dis 2009, 27:80-92.
7. Freshwater D.A., Dudley T., Cane P., Mutimer D.J. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation 2008, 85:1105-1111.
8. Hadziyannis S.J., Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001, 34:617-624.
9. Raimondo G., Navarra G., Mondello S., et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 2008, 48:743-746.
10. Brechot C., Thiers V., Kremsdorf D., Nalpas B., Pol S., Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult" ?. Hepatology 2001, 34:194-203.
11. Margeridon S., Carrouee-Durantel S., Chemin I., et al. Rolling circle amplification, a powerful tool for genetic and functional studies of complete hepatitis B virus genomes from low-level infections and for directly probing covalently closed circular DNA. Antimicrob Agents Chemother 2008, 52:3068-3073.
12. Ziakas P.D., Karsaliakos P., Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009, 94:998-1005.
13. Palmore T.N., Shah N.L., Loomba R., et al. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol 2009, 7:1130-1137.
14. Saldanha J., Gerlich W., Lelie N., Dawson P., Heermann K., Heath A. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001, 80:63-71.
15. Rizzetto M. Hepatitis D: 30years after. J Hepatol 2009, 50:1043-1050.
16. Kay A., Zoulim F. Hepatitis B virus genetic variability and evolution. Virus Res 2007, 127:164-176.
17. Mizokami M., Orito E., Ohba K., Ikeo K., Lau J.Y., Gojobori T. Constrained evolution with respect to gene overlap of hepatitis B virus. J Mol Evol 1997, 44(Suppl. 1):S83-S90.
18. Wei Y., Neveut C., Tiollais P., Buendia M.A. Molecular biology of the hepatitis B virus and role of the X gene. Pathol Biol (Paris) 2010, 58:267-272.
19. Okamoto H., Tsuda F., Sakugawa H., et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988, 69(Pt 10):2575-2583.
20. Yu H, Yuan Q, Ge SX, et al. Molecular and phylogenetic analyses suggest an additional hepatitis B virus genotype "I" PLoS One 2010;5:e9297.
21. Arankalle VA, Gandhe SS, Borkakoty BJ, Walimbe AM, Biswas D, Mahanta J. A novel HBV recombinant (genotype I) similar to Vietnam/Laos in a primitive tribe in Eastern India. J Viral Hepat 2010 [Epub ahead of print].
22. Olinger C.M., Jutavijittum P., Hubschen J.M., et al. Possible new hepatitis B virus genotype, South-East Asia. Emerg Infect Dis 2008, 14:1777-1780.
23. Hannoun C., Norder H., Lindh M. An aberrant genotype revealed in recombinant hepatitis B virus strains from Vietnam. J Gen Virol 2000, 81:2267-2272.
24. Tran T.T., Trinh T.N., Abe K. New complex recombinant genotype of hepatitis B virus identified in Vietnam. J Virol 2008, 82:5657-5663.
25. Kurbanov F., Tanaka Y., Kramvis A., Simmonds P., Mizokami M. When should "I" consider a new hepatitis B virus genotype?. J Virol 2008, 82:8241-8242.
26. Tatematsu K., Tanaka Y., Kurbanov F., et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol 2009, 83:10538-10547.
27. Kramvis A., Arakawa K., Yu M.C., Nogueira R., Stram D.O., Kew M.C. Relationship of serological subtype, basic core promoter and precore mutations to genotypes/subgenotypes of hepatitis B virus. J Med Virol 2008, 80:27-46.
28. Cui C., Shi J., Hui L., et al. The dominant hepatitis B virus genotype identified in Tibet is a C/D hybrid. J Gen Virol 2002, 83:2773-2777.
29. Abdou Chekaraou M., Brichler S.B., Mansour W., et al. A new hepatitis B virus subgenotype D (D8) strain, resulting from recombination between genotypes D and E, is circulating in Niger along with HBV/E strains. J Gen Virol 2010.
30. Schaefer S. Hepatitis B virus: significance of genotypes. J Viral Hepat 2005, 12:111-124.
31. Ganne-Carrie N., Williams V., Kaddouri H., et al. Significance of hepatitis B virus genotypes A to E in a cohort of patients with chronic hepatitis B in the Seine Saint-Denis district of Paris (France). J Med Virol 2006, 78:335-340.
32. Mayerat C., Mantegani A., Frei P.C. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection?. J Viral Hepat 1999, 6:299-304.
33. Sumi H., Yokosuka O., Seki N., et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003, 37:19-26.
34. Casey J.L., Niro G.A., Engle R.E., et al. Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. J Infect Dis 1996, 174:920-926.
35. Quintero A., Uzcategui N., Loureiro C.L., et al. Hepatitis delta virus genotypes I and III circulate associated with hepatitis B virus genotype F in Venezuela. J Med Virol 2001, 64:356-359.
36. Gomes-Gouvea M.S., Soares M.C., Bensabath G., et al. Hepatitis B virus and hepatitis delta virus genotypes in outbreaks of fulminant hepatitis (Labrea black fever) in the western Brazilian Amazon region. J Gen Virol 2009, 90:2638-2643.
37. Kato H., Ruzibakiev R., Yuldasheva N., et al. Hepatitis B virus genotypes in Uzbekistan and validity of two different systems for genotyping. J Med Virol 2002, 67:477-483.
38. Madan K., Batra Y., Sreenivas V., et al. HBV genotypes in India: do they influence disease severity?. Hepatol Res 2009, 39:157-163.
39. Cao G.W. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol 2009, 15:5761-5769.
40. Janssen H.L., van Zonneveld M., Senturk H., et al. Pegylated interferon alpha-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365:123-129.
41. Kobayashi M., Arase Y., Ikeda K., et al. Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan. J Med Virol 2002, 68:522-528.
42. Weigand K. Percutaneous liver biopsy: retrospective study over 15 years comparing 287 inpatients with 428 outpatients. J Gastroenterol Hepatol 2009, 24:792-799.
43. Poynard T., Morra R., Ingiliz P., et al. Biomarkers of liver fibrosis. Adv Clin Chem 2008, 46:131-160.
44. Lisotti A., Azzaroli F., Buonfiglioli F., Montagnani M., Alessandrelli F., Mazzella G. Lamivudine treatment for severe acute HBV hepatitis. Int J Med Sci 2008, 5:309-312.
45. Han Y., Tang Q., Zhu W., Zhang X., You L. Clinical, biochemical, immunological and virological profiles of, and differential diagnosis between, patients with acute hepatitis B and chronic hepatitis B with acute flare. J Gastroenterol Hepatol 2008, 23:1728-1733.
46. NIH consensus development statement on management of hepatitis B. NIH Consens State Sci Statements 2008;25:1-29.
47. Zoulim F., Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009, 137. 1593-608e1-2.
48. van Bommel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80.
49. Sung J.J., Wong M.L., Bowden S., et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005, 128:1890-1897.
50. Degertekin B., Lok A.S. Indications for therapy in hepatitis B. Hepatology 2009, 49:S129-S137.
51. Si Ahmed S.N., Zoulim F. Pathobiology of HBV mutants and clinical impact for treatment monitoring. Expert Rev Anti Infect Ther 2009, 7:309-320.
52. Zoulim F., Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008, 48(Suppl 1):S2-S19.
53. Flink H.J., van Zonneveld M., Hansen B.E., de Man R.A., Schalm S.W., Janssen H.L. Treatment with PEG-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006, 101:297-303.
54. Bonino F., Marcellin P., Lau G.K., et al. Predicting response to PEG-interferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007, 56:699-705.
55. Perry C.M., Simpson D. Tenofovir disoproxil fumarate: in chronic hepatitis B. Drugs 2009, 69:2245-2256.
56. Shim J.H., Lee H.C., Kim K.M., et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2009, 50:1064-1071.
57. Wong G.L., Chan H.L. Predictors of treatment response in chronic hepatitis B. Drugs 2009, 69:2167-2177.
58. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-1531.
59. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5years. Gastroenterology 2006, 131:1743-1751.
60. Baldick C.J., Eggers B.J., Fang J., et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol 2008, 48:895-902.
61. Zeuzem S., Gane E., Liaw Y.F., et al. Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009, 51:11-20.
62. Kurashige N., Ohkawa K., Hiramatsu N., et al. Two types of drug-resistant hepatitis B viral strains emerging alternately and their susceptibility to combination therapy with entecavir and adefovir. Antivir Ther 2009, 14:873-877.
63. Villet S., Billioud G., Pichoud C., et al. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology 2009, 136. 168-76 e2.
64. Villet S., Pichoud C., Billioud G., et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008, 48:747-755.
65. Warner N., Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008, 48:88-98.